Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe.

Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe. Abstract Text:

J C de Jong,D J Smith,A S Lapedes,I Donatelli,L Campitelli,G Barigazzi,K Van Reeth,T C Jones,G F Rimmelzwaan,A D M E Osterhaus,R A M Fouchier,

In the early 1970s, a human influenza A/Port Chalmers/1/73 (H3N2)-like virus colonized the European swine population. Analyses of swine influenza A (H3N2) viruses isolated in The Netherlands and Belgium revealed that in the early 1990s, antigenic drift had occurred, away from A/Port Chalmers/1/73, the strain commonly used in influenza vaccines for pigs. Here we show that Italian swine influenza A (H3N2) viruses displayed antigenic and genetic changes similar to those observed in Northern European viruses in the same period. We used antigenic cartography methods for quantitative analyses of the antigenic evolution of European swine H3N2 viruses and observed a clustered virus evolution as seen for human viruses. Although the antigenic drift of swine and human H3N2 viruses has followed distinct evolutionary paths, potential cluster-differentiating amino acid substitutions in the influenza virus surface protein hemagglutinin (HA) were in part the same. The antigenic evolution of swine viruses occurred at a rate approximately six times slower than the rate in human viruses, even though the rates of genetic evolution of the HA at the nucleotide and amino acid level were similar for human and swine H3N2 viruses. Continuous monitoring of antigenic changes is recommended to give a first indication as to whether vaccine strains may need updating. Our data suggest that humoral immunity in the population plays a smaller role in the evolutionary selection processes of swine H3N2 viruses than in human H3N2 viruses.

Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe. Publishing Authors By Initials

JC de Jong,DJ Smith,AS Lapedes,I Donatelli,L Campitelli,G Barigazzi,K Van Reeth,TC Jones,GF Rimmelzwaan,AD Osterhaus,RA Fouchier,

For similar animal diseases: swine diseases research abstracts see: animal diseases: swine diseases research

PUBMED ID PMID:

MEDLINE DATE:

Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of virology

VOLUME: 81

Page Numbers: 4315-22

Journal Abbreviation: J. Virol.

ISSN: 0022-538X

DAY: 7

MONTH: 02

YEAR: 2007

Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 113724

Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe. Keywords Mesh Terms:

KEYWORDS: Swine Diseases

MESH TERMS: virology

Chemical & Substance for Abstract: Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe. Information

Substance Name: Hemagglutinin Glycoproteins, Influenza V

Registry Number: 0

Grant and Affiliation Information for Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe.

AFFILIATION: National Influenza Center, Department of Virology, Erasmus Medical Center, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands. jc.de.jong@wxs.nl

Country: United States

AGENCY: United States NCCDPHP

GRANT: DP1-OD000490-01

ACRONYM: DP

MEDLINETA: J Virol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Antigenic and genetic evolution of swine influenza A H3N2 viruses in Europe Related Publications

• Antigenic and genetic evolution of swine influenza A (H3N2) viruses in Europe.
• Emerging influenza.
• Generation of temperature-sensitive human metapneumovirus strains that provide protective immunity in hamsters.
• Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques.
• Specificity and functional interaction of the polymerase complex proteins of human and avian metapneumoviruses.
• Vaccination approaches to combat human metapneumovirus lower respiratory tract infections.